Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Safecor Health, LLC

US Class II Ongoing · initiated 2026-05-01

Presence of a Foreign Substance; black particles observed in liquid

Safecor Health, LLC

US Class II Ongoing · initiated 2026-04-30

Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.

Ajanta Pharma Ltd.

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability …

Ajanta Pharma Ltd.

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability …

Ajanta Pharma Ltd.

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability …

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

PMS-BUSULFAN 6mg/mL

Canada Type III Ongoing · initiated 2026-04-29

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

B BRAUN MEDICAL INC

US Class I Ongoing · initiated 2026-04-28

Presence of Particulate Matter.

Oasis Medical, Inc.

US Class II Ongoing · initiated 2026-04-27

Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Exce…

Ascend Laboratories, LLC

US Class II Ongoing · initiated 2026-04-27

Failed Dissolution Specifications

Golden State Medical Supply Inc.

US Class III Ongoing · initiated 2026-04-27

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Golden State Medical Supply Inc.

US Class III Ongoing · initiated 2026-04-27

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-04-24

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufa…

Lupin Pharmaceuticals Inc.

US Class II Ongoing · initiated 2026-04-24

Presence of particulate matter: a white thread-like structure in the cartridge

Wisconsin Pharmacal Company

US Class I Ongoing · initiated 2026-04-24

Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.

Lannett Company Inc.

US Class III Ongoing · initiated 2026-04-24

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Sterile.H2O

Canada Type II Ongoing · initiated 2026-04-24

Contamination. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Thea Pharma, Inc.

US Class II Ongoing · initiated 2026-04-23

Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.

Thea Pharma, Inc.

US Class II Ongoing · initiated 2026-04-23

Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.

JB Chemicals and Pharmaceuticals Ltd

US Class II Ongoing · initiated 2026-04-23

Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-04-22

Lack of assurance of Sterility: potential product contamination

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-04-22

Lack of assurance of Sterility: potential product contamination

Alcon Research LLC

US Class II Ongoing · initiated 2026-04-21

Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.

Alcon Research LLC

US Class II Ongoing · initiated 2026-04-21

Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.